When we originally introduced the concept of selective replication over two years ago, we had promising ideas and some early data. Today, we have robust experimental results and a much clearer picture of how selective replication can be engineered reliably in RNA viruses. Back then …
Today, we’re thrilled to share a major milestone for Humane Genomics: we’ve partnered with Genezen to begin process transfer and cGMP (Current Good Manufacturing Practice) manufacturing of our lead oncolytic virus candidate for hepatoblastoma. This marks a big step forward in our mission to bring precision-engineered viral therapies to patients with cancer…
We have moved from our founding location at BioLabs@NYU Langone to Alexandria LaunchLabs, a leading life sciences innovation space in New York City. This move marks another step forward in our mission to develop next-generation oncolytic viruses for cancer therapy. Why This Move Matters Relocating our lab, to us, is more than a logistical undertaking—it […]
We recently had the opportunity to attend the 2025 American Association for Cancer Research (AACR) conference in Chicago. It is one of the largest and most prestigious gatherings in the world for cancer researchers, clinicians, and biotech companies. It was an invaluable experience—an opportunity not only to present our latest findings but also to connect […]
We showcase breakthrough data on our engineered oncolytic viral therapy, a first-in-class for pediatric liver cancer We are excited to share that Humane Genomics is returning to the American Association for Cancer Research (AACR) annual meeting for the third time! With over 23,000 attendees (in 2024), AACR is the largest gathering of cancer researchers, clinicians, […]
In our previous post on this topic, we introduced the details on how to make a replicating RNA virus from its genome (DNA). In this post, we want to zoom in on the details a bit more and share how we have improved the success rate of engineering viruses to over 70%. If you have […]
Today, the 2024 Nobel Prize in Medicine was awarded to Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNAs (miRNAs). This discovery has transformed our understanding of how cells regulate genes and opened new possibilities for diagnosing and treating diseases. But what exactly are miRNAs, and why are they so significant? What Are […]
Introduction Have you ever wondered how viruses are made in a lab setting? Although it may sound like complex wizardry, the process is quite approachable with a bit of molecular biology under your belt. This blog post will try to explain the process of engineering viruses, making it hopefully understandable to anyone curious about the […]
Rupsa and Chad presenting our poster We recently attended the American Association for Cancer Research (AACR) conference. It’s the largest cancer research gathering in the U.S., and we were thrilled to present our latest results and learn from peers. Here’s a snapshot of the current developments in oncolytic viral therapies (OVTs). The State of Oncolytic […]
We’re thrilled to announce that we’re returning to the American Association for Cancer Research (AACR) annual meeting for the second time! It’s an honor to be invited back to this prestigious event where we’ll be showcasing our groundbreaking work in the field of cancer therapeutics. AACR is the largest gathering of cancer researchers, clinicians, survivors, […]